



Gesellschaft Spanischer
Wissenschaftler in der
Bundesrepublik Deutschland

A Taste of Spanish Research

2021 CERFA Cancer Symposium

Monday 17th May

8:45 Opening

Session I. Chair: Samuel Peña-Llopis. DKTK Junior Group Leader. *Translational Genomics in Solid Tumors. University Hospital Essen. Germany*

9:00 Marisol Soengas. *Melanoma Group, CNIO, Madrid.*

“Managing and targeting premetastatic niches: applications to immunotherapy”

9:30 Juan Rodriguez-Vita. *Tumor-Stroma Communication. CIPF, Valencia and DKFZ, Heidelberg.*

“Hyaluronic acid is a master regulator of tumour stroma”

10:00 Ana Janic. *Cancer Biology. UPF, Barcelona.*

“Identification of the critical p53 tumor suppressor mechanisms”

10:30 Laura Soucek. *Mouse models of Cancer Therapies Group. VHIO, Barcelona.*

“Attacking an “Undruggable” target to combat cancer”

11:00 Selected Flash Talks

- Lena Wiedmann. “*HAPLN1 is a driver for tumor cell hyperplasticity and CAF-dependent immune-modulation in PDAC*”. German Cancer Research Center (DKFZ), Germany.
- Mónica Martínez Fernández. “*Activation of retrotransposon LINE1 is an early event in Head and Neck Squamous Cell Carcinoma*”. Galicia Sur Health Research Institute (IIGS), Spain.
- Lukas Klein. “*Inflammatory Macrophages Promote Basal-like Subtype Identity via Enhancer Reprogramming in Pancreatic Cancer*”. University medical Center Göttingen, Germany
- Elisa Donato. “*Identification of genetic, epigenetic and cellular alterations responsible for distinct clinical outcomes of DNMT3A mutant AML*”. German Cancer Research Center (DKFZ), Germany.
- Rafael Carretero Coca. “*Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1*”. German Cancer Research Center (DKFZ), Germany.

11:30 Coffee/lunch break with poster viewing in Gather



FUNDACIÓN
RAMÓN ARECES

aseica
investigando
en cáncer

Session II. Chair: Pilar Acedo. Junior Group Leader. *Institute for Liver & Digestive Health. Division of Medicine. University College London. UK*

12:30 Roger Gomis. *Growth Control and Cancer Metastasis. IRB, Barcelona.*

“Metastasis latency in breast cancer”

13:00 María M Caffarel. *Breast Cancer Group. Biodonostia Health Research Institute, Donostia-San Sebastián.*

“Stromal Oncostatin M axis promotes breast cancer progression and tumour-promoting inflammation”

13:30 Toni Celià-Terrassa. *Cancer Stem Cells and Metastasis Dynamics. IMIM, Barcelona.*

“Tumor plasticity implications in breast cancer immunity”

14:00 Concluding remarks of the day

Tuesday 18th May

Session III Chair: Juan Rodríguez-Vita. Junior Group leader, *Tumor-Stroma Communication Group, CIPF, Valencia.* Project Leader, *Vascular signalling and Cancer, DKFZ, Heidelberg*

9:00 Manuel Valiente. *Brain Metastasis Group. CNIO, Madrid.*

“Strategies to challenge brain metastasis lethality in mice and human”

9:30 Sònia Guedan. *Hematopoietic Progenitor Cell Transplantation. IDIBAPS, Barcelona.*

“CAR-T cell therapy: Engineering immune cells to fight cancer”

10:00 Arkaitz Carracedo. *Cancer Cell Signalling and Metabolism Group. CIC bioGUNE, Bizkaia.*

“Metabolic and signaling drivers of prostate cancer progression”

10:30 – 12:00 *Poster viewing + coffee/lunch time*

12:00 – 12:15 *Poster evaluation*

Session IV Chair: Elisa Espinet. Senior Postdoctoral Researcher. *Stem Cells and Cancer, DKFZ and HI-STEM, Heidelberg*

12:20 Maite Huarte. *Long noncoding RNA and Gene Regulation in Cancer. CIMA, Navarra.*

“Chromatin-related functions of lncRNAs in the regulation of cancer pathways”

12:50 María Abad. *Cellular Plasticity and Cancer Group. VHIO, Barcelona.*

“Mining the cancer microprotome for novel drivers of cancer cell plasticity”

13:20 *Poster prize and concluding remarks*



FUNDACIÓN
RAMÓN ARECES

aseica
investigando
en cáncer

Posters

#	Title	Presenter	Affiliation
P01	<i>Essential role of endothelial Notch activation in the re-education of tumor associated macrophages</i>	Elisenda Alsina-Sanchis	German Cancer Research Center (DKFZ), Germany
P02	<i>HAPLN1 is a driver for tumor cell hyperplasticity and CAF-dependent immune-modulation in PDAC</i>	Lena Wiedmann	German Cancer Research Center (DKFZ), Germany
P03	<i>L1CAM reduces tumorigenicity, stemness and fibrosis in pancreatic ductal adenocarcinoma</i>	Donatella Delle Cave	Institute of Genetics and Biophysics "A. Buzzati Traverso" (IGB-ABT), Italy
P04	<i>Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell-of-origin</i>	Elisa Espinet	German Cancer Research Center (DKFZ), Germany
P05	<i>Activation of retrotransposon line1 is an early event in head and neck squamous cell carcinoma</i>	Monica Martinez Fernandez	Galicia Sur Health Research Institute (IISGS), Spain
P06	<i>mRNA vaccination platform for cancer therapeutics based on proprietary polymeric nanoparticles platform</i>	Cristina Fornaguera	Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Spain
P07	<i>Multimodal clinical mass Spectrometry to TArget treatment ReSistance</i>	Álvaro Fernández Ochoa	Max Delbrück Center for Molecular Medicine, Germany
P08	<i>ERK2 drives MYC expression acting as a kinase-independent anchor for CDK9 at the MYC promoter</i>	Marta Morante Ezquerro	IBBTEC, Spain
P09	<i>Characterization of the role of innate lymphoid cells in nonalcoholic fatty liver disease</i>	Xin Li	German Cancer Research Center (DKFZ), Germany
P10	<i>Delivery of Galunisertib to colorectal cancer cells by biosilica porous nanoparticles</i>	Chiara Tramontano	National Research Council of Naples, Italy
P11	<i>The LATS1 and LATS2 tumor suppressor kinases: a comprehensive multilayered MS-based analysis of their functional roles in breast cancer</i>	Bianca Kuhn	German Cancer Research Center (DKFZ), Germany

P12	<i>Identification of resistance mechanisms and vulnerabilities to the mitotic inhibitor Rigosertib (ON-01910.Na)</i>	Ana Monfort-Vengut	Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC, Spain
P13	<i>Inflammatory Macrophages Promote Basal-like Subtype Identity via Enhancer Reprogramming in Pancreatic Cancer</i>	Lukas Klein	University Medical Center Göttingen, Germany
P14	<i>Identification of genetic, epigenetic and cellular alterations responsible for distinct clinical outcomes of DNMT3A mutant AML</i>	Elisa Donato	German Cancer Research Center (DKFZ), Germany
P15	<i>Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1</i>	Rafael Carretero Coca	German Cancer Research Center (DKFZ), Germany
P16	<i>A new label-free strategy to detect circulating tumor cells</i>	Maria Mangini	Institute of Biochemistry and Cell Biology, National Research Council, Italy
P17	<i>A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis</i>	Samuel Peña-Llopis	German Cancer Consortium (DKTK) at University Hospital Essen, Germany
P18	<i>Integration of drug repurposing and pairwise screening unveils combinatorial therapies for mutant KRAS lung cancer</i>	Silvestre Vicent Cambra	Center for Applied Medical Research (CIMA-University of Navarra), Spain
P19	<i>Endomembranes promote chromosome missegregation by ensheathing misaligned chromosomes</i>	Nuria Ferrandiz	University of Warwick, UK
P20	<i>Sex oriented functional meta-analysis of non-small cell lung cancer transcriptomics studies</i>	Marta R. Hidalgo	Principe Felipe Research Center (CIPF), Valencia, Spain
P21	<i>Tumor localized 4-1BB stimulation for effective cancer immunotherapy</i>	Aizea Morales-Kastresana	Pieris Pharmaceuticals, Germany



FUNDACIÓN
RAMÓN ARECES

